Fig. 12.1 The history of primary chemotherapy for epithelial ovarian cancer In contrast to paclitaxel, fractionated weekly dosing of carboplatin remains a challenging regimen. The Multicentre Italian Trials in Ovarian…
Author Year Number of patients Positive rate(%) Stage (%) Positive rate(%) la lb lc PEN PAN Sakuragi, et al 2000 78 5.1 3.2 – 6.4 0 5.1 Suzuki, et al…
High-grade serous Low-grade serous High-grade endometrioid Low-grade endometrioid Clear cell Mucinous Unspecified carcinoma No. 1501 70 64 14 58 16 166 BRCA1 (%) 10.3 4.3 6.3 0 6.9 0…
Fig. 8.1 Flowchart of fundamental strategies for the management of epithelial ovarian cancer. Cited from Komiyama et al. [3] with slight modifications 8.2 Surgical Management 8.2.1 Early (Localized to the Ovary)-Staged…
St Bartholomew’s Hospital trial The Boston study Ref. [9] [10] Published 1996 2003 Design Single arm prospective study Single arm prospective study. Subjects The low-risk asymptomatic women > or = 45 years…
Fig. 7.1 HR-deficient and HR-proficient tumors of high-grade serous ovarian carcinoma [8] HR pathway proficient tumors with CCNE1 amplification were common in primary resistant and refractory cases [7]. Inactivation of…
Amount of fibroglandular tissue (FGT) Almost entirely fat Scattered fibroglandular tissue Heterogeneous fibroglandular tissue Extreme fibroglandular tissue Background Parenchymal Enhancement Level Minimal Mild Moderate Marked Symmetric or Asymmetric Focus Masses…
Fig. 15.1 7 T DCE. Invasive ductal carcinoma G2 in a 50-year-old woman at 1 o’clock in the right breast. (a) At DCE MRI of the breast at 7 T…
TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ Tis (DCIS) Ductal carcinoma in situ Tis (LCIS) Lobular carcinoma in situ Tis (Paget’s)…
Fig. 8.1 Typical timeline of mammographic (MG) findings following Breast Conservation Therapy Early findings of postoperative collections such as seroma and/or hematoma, breast edema and skin thickening, are most pronounced…
